The mid-year conference’s goal was to bring together a promising group of 75 private and microcap companies in 25 different healthcare sectors with a prominent group of European and U.S. institutional investor groups.
One type of nanoparticle currently in development engages in “active targeting,” or targeting drugs to cancer cells by attaching them to a molecule that the cancer cell is receptive to.
GenVec’s experimental drug to treat pancreatic cancer has been granted orphan drug status by the U.S. Food and Drug Administration.
Scientists in Switzerland may have found a way to inhibit the growth of colon cancer in humans, says a new study published in EMBO Molecular Medicine.
Copyright © 2025 | WordPress Theme by MH Themes